155 related articles for article (PubMed ID: 28192404)
41. Inactivation of RASA1 promotes melanoma tumorigenesis via R-Ras activation.
Sung H; Kanchi KL; Wang X; Hill KS; Messina JL; Lee JH; Kim Y; Dees ND; Ding L; Teer JK; Yang S; Sarnaik AA; Sondak VK; Mulé JJ; Wilson RK; Weber JS; Kim M
Oncotarget; 2016 Apr; 7(17):23885-96. PubMed ID: 26993606
[TBL] [Abstract][Full Text] [Related]
42. Lidocaine exerts anticancer activity in bladder cancer by targeting isoprenylcysteine carboxylmethyltransferase (
Teng X; Liu Y; Wang L; Wang G
Transl Androl Urol; 2021 Nov; 10(11):4219-4230. PubMed ID: 34984187
[TBL] [Abstract][Full Text] [Related]
43. Knock-in of mutant K-ras in nontumorigenic human epithelial cells as a new model for studying K-ras mediated transformation.
Konishi H; Karakas B; Abukhdeir AM; Lauring J; Gustin JP; Garay JP; Konishi Y; Gallmeier E; Bachman KE; Park BH
Cancer Res; 2007 Sep; 67(18):8460-7. PubMed ID: 17875684
[TBL] [Abstract][Full Text] [Related]
44. MicroRNAs targeting mutant K-ras by electrotransfer inhibit human colorectal adenocarcinoma cell growth in vitro and in vivo.
Vidic S; Markelc B; Sersa G; Coer A; Kamensek U; Tevz G; Kranjc S; Cemazar M
Cancer Gene Ther; 2010 Jun; 17(6):409-19. PubMed ID: 20094071
[TBL] [Abstract][Full Text] [Related]
45. Functionalized indoleamines as potent, drug-like inhibitors of isoprenylcysteine carboxyl methyltransferase (Icmt).
Ramanujulu PM; Yang T; Yap SQ; Wong FC; Casey PJ; Wang M; Go ML
Eur J Med Chem; 2013 May; 63():378-86. PubMed ID: 23514631
[TBL] [Abstract][Full Text] [Related]
46. Post-prenylation-processing enzymes as new targets in oncogenesis.
Winter-Vann AM; Casey PJ
Nat Rev Cancer; 2005 May; 5(5):405-12. PubMed ID: 15864282
[TBL] [Abstract][Full Text] [Related]
47. KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.
Kenessey I; Kói K; Horváth O; Cserepes M; Molnár D; Izsák V; Dobos J; Hegedűs B; Tóvári J; Tímár J
Oncotarget; 2016 Nov; 7(48):79503-79514. PubMed ID: 27780929
[TBL] [Abstract][Full Text] [Related]
48. Isoprenylcysteine carboxyl methyltransferase deficiency in mice.
Bergo MO; Leung GK; Ambroziak P; Otto JC; Casey PJ; Gomes AQ; Seabra MC; Young SG
J Biol Chem; 2001 Feb; 276(8):5841-5. PubMed ID: 11121396
[TBL] [Abstract][Full Text] [Related]
49. [Study of growth inhibition of lung cancer cells by siRNA targeting mutant K-ras gene in vitro and in vivo].
Zhang ZP; Jiang GC; Yang F; Zhou ZL; Wang J
Zhonghua Wai Ke Za Zhi; 2007 Sep; 45(18):1267-70. PubMed ID: 18067742
[TBL] [Abstract][Full Text] [Related]
50. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
[TBL] [Abstract][Full Text] [Related]
51. Phosphorylation at Ser-181 of oncogenic KRAS is required for tumor growth.
Barceló C; Paco N; Morell M; Alvarez-Moya B; Bota-Rabassedas N; Jaumot M; Vilardell F; Capella G; Agell N
Cancer Res; 2014 Feb; 74(4):1190-9. PubMed ID: 24371225
[TBL] [Abstract][Full Text] [Related]
52. Differential functions of Ras for malignant phenotypic conversion.
Moon A
Arch Pharm Res; 2006 Feb; 29(2):113-22. PubMed ID: 16526274
[TBL] [Abstract][Full Text] [Related]
53. Activation of sterile20-like kinase 1 in proteasome inhibitor bortezomib-induced apoptosis in oncogenic K-ras-transformed cells.
Teraishi F; Guo W; Zhang L; Dong F; Davis JJ; Sasazuki T; Shirasawa S; Liu J; Fang B
Cancer Res; 2006 Jun; 66(12):6072-9. PubMed ID: 16778179
[TBL] [Abstract][Full Text] [Related]
54. STAT1 represses Skp2 gene transcription to promote p27Kip1 stabilization in Ras-transformed cells.
Wang S; Raven JF; Koromilas AE
Mol Cancer Res; 2010 May; 8(5):798-805. PubMed ID: 20407011
[TBL] [Abstract][Full Text] [Related]
55. Comparison of liver oncogenic potential among human RAS isoforms.
Chung SI; Moon H; Ju HL; Kim DY; Cho KJ; Ribback S; Dombrowski F; Calvisi DF; Ro SW
Oncotarget; 2016 Feb; 7(6):7354-66. PubMed ID: 26799184
[TBL] [Abstract][Full Text] [Related]
56. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro.
End DW; Smets G; Todd AV; Applegate TL; Fuery CJ; Angibaud P; Venet M; Sanz G; Poignet H; Skrzat S; Devine A; Wouters W; Bowden C
Cancer Res; 2001 Jan; 61(1):131-7. PubMed ID: 11196150
[TBL] [Abstract][Full Text] [Related]
57. Purification, functional reconstitution, and characterization of the Saccharomyces cerevisiae isoprenylcysteine carboxylmethyltransferase Ste14p.
Anderson JL; Frase H; Michaelis S; Hrycyna CA
J Biol Chem; 2005 Feb; 280(8):7336-45. PubMed ID: 15611058
[TBL] [Abstract][Full Text] [Related]
58. Probing the isoprenylcysteine carboxyl methyltransferase (Icmt) binding pocket: sulfonamide modified farnesyl cysteine (SMFC) analogs as Icmt inhibitors.
Majmudar JD; Hahne K; Hrycyna CA; Gibbs RA
Bioorg Med Chem Lett; 2011 May; 21(9):2616-20. PubMed ID: 21334890
[TBL] [Abstract][Full Text] [Related]
59. Amide-modified prenylcysteine based Icmt inhibitors: Structure-activity relationships, kinetic analysis and cellular characterization.
Majmudar JD; Hodges-Loaiza HB; Hahne K; Donelson JL; Song J; Shrestha L; Harrison ML; Hrycyna CA; Gibbs RA
Bioorg Med Chem; 2012 Jan; 20(1):283-95. PubMed ID: 22142613
[TBL] [Abstract][Full Text] [Related]
60. Lipid and sulfur substituted prenylcysteine analogs as human Icmt inhibitors.
Bergman JA; Hahne K; Hrycyna CA; Gibbs RA
Bioorg Med Chem Lett; 2011 Sep; 21(18):5616-9. PubMed ID: 21782433
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
